title: How innate immune mechanisms contribute to antibody-enhanced viral infections.
abstract: Preexisting antibodies may enhance viral infections. In dengue, nonneutralizing antibodies raised by natural infection with one of four dengue viruses (DENVs) may enhance infection with a different virus by a process we term "intrinsic antibody-dependent enhancement" (iADE). In addition, nonprotective antibodies raised by formalin-inactivated respiratory syncytial virus (RSV) and measles virus vaccines have led to enhanced disease during breakthrough infections. Infections under iADE conditions not only facilitate the process of viral entry into monocytes and macrophages but also modify innate and adaptive intracellular antiviral mechanisms, suppressing type 1 interferon (IFN) production and resulting in enhanced DENV replication. The suppression observed in vitro has been documented in patients with severe (dengue hemorrhagic fever [DHF]) but not in patient with mild (dengue fever [DF]) secondary dengue virus infections. Important veterinary viral infections also may exhibit iADE. It is thought that use of formalin deconforms viral epitopes of RSV, resulting in poor Toll-like receptor (TLR) stimulation; suboptimal maturation of dendritic cells with reduced production of activation factors CD40, CD80, and CD86; decreased germinal center formation in lymph nodes; and the production of nonprotective antibodies. These antibodies fail to neutralize RSV, allowing replication with secondary stimulation of RSV-primed Th2 cells producing more low-avidity antibody, resulting in immune complexes deposited into affected tissue. However, when formalin-inactivated RSV was administered with a TLR agonist to mice, they were protected against wild-type virus challenge. Safe and effective vaccines against RSV/measles virus and dengue virus may benefit from a better understanding of how innate immune responses can promote production of protective antibodies.
authors.affiliation: Microbiology Department, Faculty of Science, Mahidol University, 272 Rama 6 Road, Bangkok 10400, Thailand.
authors.forename: Sukathida
authors.initials: S
authors.lastname: Ubol
authors.forename: Scott B
authors.initials: SB
authors.lastname: Halstead
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology*; D019067:Antibody-Dependent Enhancement; D006801:Humans; D007108:Immune Tolerance; D007113:Immunity, Innate; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology; D014777:Virus Diseases / Q000276:immunology* / Q000473:pathology*; D014780:Viruses / Q000276:immunology* / Q000472:pathogenicity*
chemical_list: D019138:Antibodies, Blocking; D014765:Viral Vaccines